###begin article-title 0
Biomarkers of Endocannabinoid System Activation in Severe Obesity
###end article-title 0
###begin p 1
Conceived and designed the experiments: JCS BFC JW. Performed the experiments: TMS SM GMS. Analyzed the data: JCS OH BFC JW. Contributed reagents/materials/analysis tools: JCS TMS SM GMS BFC JW. Wrote the paper: JCS JW. Coordinated all experiments and work: JCS. Advised on all metabolite experiments: BFC.
###end p 1
###begin p 2
Current address: Moores Cancer Center, University of California San Diego, La Jolla, California, United States of America
###end p 2
###begin title 3
Background
###end title 3
###begin p 4
###xml 518 522 518 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
Obesity is a worldwide epidemic, and severe obesity is a risk factor for many diseases, including diabetes, heart disease, stroke, and some cancers. Endocannabinoid system (ECS) signaling in the brain and peripheral tissues is activated in obesity and plays a role in the regulation of body weight. The main research question here was whether quantitative measurement of plasma endocannabinoids, anandamide, and related N-acylethanolamines (NAEs), combined with genotyping for mutations in fatty acid amide hydrolase (FAAH) would identify circulating biomarkers of ECS activation in severe obesity.
###end p 4
###begin title 5
Methodology/Principal Findings
###end title 5
###begin p 6
###xml 101 102 99 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 156 157 152 153 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 278 282 274 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 337 341 333 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 418 422 412 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 468 470 462 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C/</italic>
###xml 647 651 639 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 732 736 722 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 272 277 <span type="species:ncbi:9606">human</span>
Plasma samples were obtained from 96 severely obese subjects with body mass index (BMI) of >/=40 kg/m2, and 48 normal weight subjects with BMI of </=26 kg/m2. Triple-quadrupole mass spectroscopy methods were used to measure plasma ECS analogs. Subjects were genotyped for human FAAH gene mutations. The principal analysis focused on the FAAH 385 C-->A (P129T) mutation by comparing plasma ECS metabolite levels in the FAAH 385 minor A allele carriers versus wild-type C/C carriers in both groups. The main finding was significantly elevated mean plasma levels of anandamide (15.1+/-1.4 pmol/ml) and related NAEs in study subjects that carried the FAAH 385 A mutant alleles versus normal subjects (13.3+/-1.0 pmol/ml) with wild-type FAAH genotype (p = 0.04), and significance was maintained after controlling for BMI.
###end p 6
###begin title 7
Conclusions/Significance
###end title 7
###begin p 8
###xml 112 116 112 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 162 166 162 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 255 259 255 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 362 366 362 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 469 475 <span type="species:ncbi:9606">humans</span>
Significantly increased levels of the endocannabinoid anandamide and related NAEs were found in carriers of the FAAH 385 A mutant alleles compared with wild-type FAAH controls. This evidence supports endocannabinoid system activation due to the effect of FAAH 385 mutant A genotype on plasma AEA and related NAE analogs. This is the first study to document that FAAH 385 A mutant alleles have a direct effect on elevated plasma levels of anandamide and related NAEs in humans. These biomarkers may indicate risk for severe obesity and may suggest novel ECS obesity treatment strategies.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 288 291 288 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Mechoulam1">[1]</xref>
###xml 292 295 292 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Martin1">[4]</xref>
###xml 502 505 502 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-DiMarzo2">[5]</xref>
###xml 506 509 506 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-RodriguezdeFonseca1">[7]</xref>
###xml 892 895 892 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-DiMarzo1">[2]</xref>
###xml 897 900 897 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-RodriguezdeFonseca1">[7]</xref>
###xml 901 905 901 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Walker1">[10]</xref>
###xml 1192 1195 1192 1195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-DiMarzo2">[5]</xref>
###xml 1197 1200 1197 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-RodriguezdeFonseca1">[7]</xref>
###xml 1202 1206 1202 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Cravatt1">[11]</xref>
###xml 376 382 <span type="species:ncbi:9606">humans</span>
Endocannabinoids (ECs) are a family of polyunsaturated fatty acid derivatives that function as lipid signaling molecules by acting as endogenous ligands at the two known cannabinoid receptors (CBRs), CB1 and CB2, present in the nervous system and peripheral organs of many living species [1]-[4]. The endocannabinoid system (ECS) is highly developed in mammals, especially in humans, and the physiology and pharmacology of the ECS have been the subject of several comprehensive reviews in recent years [5]-[7]. The most well-studied of the ECs are the fatty acid amides (FAAs) represented by N-arachidonyl ethanolamine (AEA) or anandamide, N-palmitoyl ethanolamine (PEA), N-oleoyl ethanolamine (OEA) and related N-acylethanolamine (NAE) derivatives together with the esters of arachidonic acid including 2-arachidonyl glycerol (2-AG) as well as other lipid signaling molecules acting at CBRs [2], [7]-[10]. Some of these ECs are known to modulate a variety of physiological functions including synaptic transmission, immune function, nociception, fertility, and cardiovascular function, in addition to nervous system development, and are involved in many pathophysiological disease processes [5], [7], [11].
###end p 10
###begin p 11
###xml 178 181 178 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-DiMarzo3">[6]</xref>
###xml 183 187 183 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Cravatt1">[11]</xref>
###xml 229 235 229 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(FAAH)</italic>
###xml 261 267 261 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(MGLL)</italic>
###xml 496 500 496 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-OseiHyiaman1">[12]</xref>
###xml 501 505 501 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Engeli2">[17]</xref>
###xml 670 674 670 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Engeli2">[17]</xref>
###xml 535 540 <span type="species:ncbi:9606">human</span>
The complex biosynthetic and enzymatic degradation pathways for these ECS signaling molecules are currently being investigated as potentially selective disease treatment targets [6], [11], particularly fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGLL), which are the principal inactivating enzymes for FAAs and 2-AG. There is an increasing body of data on endocannabinoid control of energy homeostasis and recent evidence for ECS dysregulation in overweight and obesity disorders [12]-[17]. It has become apparent that human obesity is associated with activation of the ECS and with increased levels of ECs in many tissues, as well as in the circulation [17] However, the underlying molecular mechanisms of ECS dysregulation in obesity need clarification to better understand ECS risk factors in obesity and to develop novel selective treatment strategies.
###end p 11
###begin p 12
###xml 207 211 207 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Kirkham1">[18]</xref>
###xml 213 217 213 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Kunos1">[19]</xref>
###xml 454 457 454 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-DiMarzo4">[8]</xref>
###xml 788 792 788 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Kunos1">[19]</xref>
###xml 977 981 977 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Roche1">[20]</xref>
###xml 983 987 983 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Gonthier1">[21]</xref>
###xml 1040 1044 1040 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-OseiHyiaman1">[12]</xref>
###xml 1073 1077 1073 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Lo1">[22]</xref>
###xml 1217 1221 1217 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Gaetani1">[15]</xref>
###xml 1287 1291 1287 1291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Bellocchio1">[16]</xref>
###xml 1315 1319 1315 1319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Matias1">[23]</xref>
###xml 292 298 <span type="species:ncbi:9606">humans</span>
Current concepts in this field indicate that body weight and fat metabolism are influenced by complex ECS regulatory mechanisms that modulate energy balance, feeding behavior and peripheral lipid metabolism [18], [19]. The ECS comprises one of the most important weight regulatory systems in humans, since endocannabinoids have numerous effects on energy homeostasis by activating cannabinoid receptors throughout the nervous system and in the periphery [8] together with modulation of other downstream energy regulating molecules. In the mammalian brain, ECs modulate appetite via leptin-regulated circuits in the lateral hypothalamus or by direct activation of the mesolimbic dopamine "reward" pathways for food intake and thus may increase feeding behavior in animal models of obesity [19]. In mammalian peripheral tissues, ECs may have direct effects, for example in adipose tissue where CB1 receptors are located and ECS biosynthetic and degradative enzymes are expressed [20], [21], in the liver where ECs promote hepatic lipogenesis [12], in the intestine where OEA [22], the monounsaturated analogue of anandamide has the opposite or anorexic effect of decreasing food intake and body weight in animal models [15], as well as ECS effects in other tissues such as skeletal muscle [16] and endocrine pancreas [23].
###end p 12
###begin p 13
###xml 111 115 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-DiMarzo6">[24]</xref>
###xml 209 213 209 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Monteleone1">[25]</xref>
###xml 332 336 332 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Engeli3">[26]</xref>
###xml 506 510 506 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Cote1">[27]</xref>
###xml 571 575 571 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 625 629 625 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Engeli3">[26]</xref>
###xml 740 744 740 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Engeli2">[17]</xref>
###xml 76 81 <span type="species:ncbi:9606">human</span>
###xml 176 181 <span type="species:ncbi:9606">women</span>
###xml 288 293 <span type="species:ncbi:9606">women</span>
###xml 311 316 <span type="species:ncbi:9606">women</span>
###xml 351 356 <span type="species:ncbi:9606">human</span>
###xml 386 389 <span type="species:ncbi:9606">men</span>
Recent investigations have demonstrated activation of the peripheral ECS in human obesity and type II diabetes [24] as well as increased circulating plasma AEA levels in young women with binge eating disorder [25]. Increased plasma AEA and 2-AG levels have been found in obese menopausal women compared to lean women of similar age [26]. A study in a human visceral obesity disorder in men has shown elevated plasma fasting levels of 2-AG but not AEA as measured by liquid chromatography-mass spectroscopy [27]. Also, a strong negative correlation has been found between FAAH expression in adipose tissue and circulating ECs [26]. Other studies of plasma AEA and 2-AG levels have shown no relationship with obesity or body fat distribution [17], but these findings may be related to differences in methodology or obesity phenotypes in the study cohorts. Importantly, the pathophysiological role of circulating endocannabinoids as risk factors for obesity remains to be elucidated.
###end p 13
###begin p 14
###xml 379 383 379 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 388 392 388 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MGLL</italic>
###xml 483 487 483 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 557 561 555 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Sipe1">[28]</xref>
###xml 665 675 663 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P129T FAAH</italic>
###xml 675 679 673 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Chiang1">[29]</xref>
###xml 740 749 738 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH gene</italic>
###xml 477 482 <span type="species:ncbi:9606">human</span>
###xml 659 664 <span type="species:ncbi:9606">human</span>
The overall aim of the present study was to investigate circulating biomarkers of ECS activation in severely obese subjects compared to normal weight controls using highly sensitive triple-quadrupole mass spectroscopy plasma quantification methods, combined with genotyping for common mutations in the genes encoding the endocannabinoid and fatty acid amide inactivating enzymes FAAH and MGLL. This aim is based on our previous reports that showed an association of the common human FAAH 385 C-->A (P129T)non-synonymous mutation with overweight and obesity [28] and biochemical evidence of approximately 50% reduced cellular expression and activity of mutant human P129T FAAH[29]. This study achieved the aim of identifying both plasma and FAAH gene ECS biomarkers of severe obesity that have the potential to be clinically useful if confirmed by larger studies.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Objectives
###end title 16
###begin p 17
###xml 452 456 452 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 507 511 507 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
The objective of this study was to investigate readily available circulating biomarkers of ECS activation in severely obese subjects compared to normal weight subjects by combining accurate measurement of plasma endocannabinoid levels with SNP genotyping in critical ECS inactivating enzymes. The main hypothesis herein based on previous studies was that plasma levels of anandamide and related NAEs would be elevated in severely obese carriers of the FAAH 385 A alleles compared to normal weight wild-type FAAH carriers. This evidence could further support ECS activation in a sub-type of severely obese individuals and may indicate novel ECS treatment targets in severe obesity.
###end p 17
###begin title 18
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
Participants
###end title 18
###begin p 19
###xml 858 859 858 859 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 870 871 870 871 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1026 1027 1026 1027 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1474 1484 1474 1484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008792.s001">Dataset S1</xref>
###xml 929 932 <span type="species:ncbi:9606">men</span>
###xml 947 952 <span type="species:ncbi:9606">women</span>
###xml 1089 1092 <span type="species:ncbi:9606">men</span>
###xml 1106 1111 <span type="species:ncbi:9606">women</span>
###xml 1233 1240 <span type="species:ncbi:9606">patient</span>
###xml 1350 1362 <span type="species:ncbi:9606">participants</span>
Samples and linked biometric data used in this study were obtained from the rimonabant (Acomplia) CRESCENDO study (), a cardiovascular outcomes trial to assess the efficacy of the CB1 receptor antagonist, rimonabant (Acomplia), in reducing the risk of heart attack, stroke, or cardiovascular death in abdominally obese individuals and comprised 18,671 randomized and treated subjects and was conducted by Sanofi-Aventis. Subjects and samples for this study were from a subset of 3101 subjects who volunteered with separate written informed consent for the CRESCENDO Genomic Substudy cohort. A subset of the substudy were selected for this ECS study based on BMI (150 with BMI<30 and 150 with BMI>40). Severely obese subjects for this ECS metabolite and genomics study were selected from the Genomic Substudy cohort based on a body mass index (BMI) of 40 kg/m2 to 60 kg/m2 and waist circumference of greater or equal to 140 cm in men and 131 cm in women. Normal weight controls were included based on a BMI of less than 26 kg/m2 and a waist circumference of less than or equal to 100 cm in men and 90 cm in women. To reduce false-positive findings due to differing genetic backgrounds, and since Whites were highly represented in the patient population sampled, the study was limited to male and female Whites, ranging in age from 55 to 77. All study participants and data were anonymous and biometric data were linked to each plasma and DNA sample by unique study code (see Dataset S1). The anonymous biometric data and the subjects' samples were obtained with broad informed consent approved by the Institutional Review Board (IRB)/EC for the site and use of anonymous samples in the current study received additional approval from the Scripps IRB.
###end p 19
###begin title 20
Procedures: Plasma Endocannabinoid and NAE Analysis
###end title 20
###begin p 21
###xml 723 724 711 712 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 801 802 789 790 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 805 806 793 794 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
Whole blood samples were collected in evacuated glass tubes containing EDTA. Samples were centrifuged to separate plasma from blood cells and plasma was withdrawn and stored in 1 ml aliquots at -80degreesC prior to plasma lipid extraction. For each sample, 0.5 ml plasma was added to a glass vial containing 2.0 ml chloroform (CHCl3), 1.0 ml methanol (MeOH) and 0.5 ml (1% v/v) formic acid. To this mixture were added aliquots of 10 pmol D5-2-arachidonlyglycerol (2-AG) and 5 pmol D8-arachidonlyethanolamine (AEA). Vial contents were vortex mixed for 30 seconds and centrifuged at 10degreesC (1400xg for 10 minutes). The organic layer was carefully removed avoiding the aqueous layer and dried under a stream of nitrogen (N2) gas. The lipid layer was then re-solubilized in 100 microliters of 2:1 CHCl3:CH3OH.
###end p 21
###begin p 22
###xml 209 213 209 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Palandra1">[30]</xref>
###xml 713 714 713 714 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 755 756 755 756 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 856 858 856 858 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">18</sup>
###xml 1231 1235 1231 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Palandra1">[30]</xref>
Quantitative analysis of endocannabinoids and NAE analogues using the deuterated standards for AEA and 2-AG together with calculation of the other EC analogues was based on a ratio to the deuterated standards [30] and was performed on the Agilent 6410 Triple Quadrupole Liquid Chromatography-Mass Spectroscopy (TQMS) instrument using positive ion analysis mode. For each sample, 20 microliters of re-solubilized plasma lipids were injected into the TQMS instrument and EC congeners were measured by multiple reaction monitoring (MRM) using the following transitions: 348>62 (AEA), fragmentation energy = 8, and 379>287 (2-AG), fragmentation energy = 11. Chromatography was performed using the following solvents: A - 95:5:0.1 H20:methanol:formic acid and B - 60:35:5:0.1 isopropanol:methanol:H2O:formic acid. Lipids were injected into a 5 microcentimeter C18 column (50x4.6 mm) from Phenomenex (Torrance, CA) and eluted with a 10 minute solvent B gradient from 60% to 100%. Values for each endocannabinoid and NAE analogue were subsequently calculated using ratios to the deuterated internal standards to calculate absolute concentrations, expressed as picomoles (pmol) of EC metabolite per ml of plasma similar to current methods [30].
###end p 22
###begin title 23
Procedures: FAAH and MAGL SNP Genotyping Methods and Study Subjects
###end title 23
###begin p 24
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MGLL</italic>
###xml 268 272 268 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 283 287 283 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MGLL</italic>
###xml 387 394 <span type="species:ncbi:9606">patient</span>
Genotyping of the SNPs in the FAAH (GeneID 2166) and MGLL (GeneID 11343) from dbSNP was performed using the Sequenom platform. The major allele frequencies were determined in all 300 obese and normal subjects, using the Sequenom data for detection of 4 common SNPs in FAAH and 16 in MGLL (data not shown). To reduce false-positive findings due to differing genetic backgrounds, the same patient population used for the EC metabolite analysis was sampled and only male and female Whites were included, as noted above.
###end p 24
###begin title 25
Procedures: Statistical Methods
###end title 25
###begin p 26
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">apriori</italic>
###xml 199 203 199 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Kaufmann1">[31]</xref>
###xml 172 178 <span type="species:ncbi:9606">humans</span>
The apriori or pre-study power calculation to detect a true association in this study was based upon estimations from data reported for measurement of anandamide levels in humans in a clinical trial [31]. Using a standard deviation (SD) for anandamide of approximately 4 pmoles/ml, the power was 0.9 to detect a difference of 2.2 pmoles/ml (standardized difference 0.53) and power of 0.8 to detect a difference of 1.8 pmoles/ml (standardized difference 0.45) at alpha = 0.05 with an expected total sample size of 150.
###end p 26
###begin p 27
###xml 420 424 420 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 591 595 591 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 818 822 818 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
The distribution of each metabolite was assessed for outliers and normality. Log transformation of data resulted in normal distributions for all EC analogues. Stratification revealed no significant differences in mean metabolite levels by age and sex and these variables were thus not included in further analyses. Geometric means of each metabolite were compared between BMI groups using the t-test. Frequencies of the FAAH genotype were compared between the severely obese and normal weight groups using the Fisher's exact test. Geometric mean levels of EC analogues were compared between FAAH genotype groups (carriers of the minor "A" allele compared with subjects with the wild type genotype C/C) in both BMI groups combined using the t-test and stratified by BMI group using 2-Way ANOVA. Normal weight wild-type FAAH subjects were compared with severely obese carriers of the FAAH 385 mutant A allele using 1-Way ANOVA with Dunnett's Correction for multiple comparisons. A two-sided p-value <0.05 was considered statistically significant.
###end p 27
###begin title 28
Ethics
###end title 28
###begin p 29
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
Participants in this study initially gave broad written informed consent for collection and analysis of plasma and DNA for the Sanofi-Aventis CRESCENDO Genomic Substudy. In this study of EC analogues, all subjects were anonymous and identified only by a code number linked to biometric data. Because informed consent from strictly anonymous CRESCENDO study subjects was not possible, the present study received an exemption for additional written consent from the Scripps IRB.
###end p 29
###begin title 30
Results
###end title 30
###begin title 31
Endocannabinoid and NAE Levels
###end title 31
###begin p 32
###xml 127 134 127 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008792-t001">Table 1</xref>
Demographic characteristics of the 96 severely obese subjects and 48 normal weight controls included in the study are shown in Table 1. The severely obese group had a mean age that was approximately 5 years younger than the normal weight group (p<0.0001). Other variables including the percentage of male subjects (44% in severely obese vs. 35% in the normal weight group) were not statistically different.
###end p 32
###begin title 33
Demographic Characteristics of EC Metabolite Study Subjects.
###end title 33
###begin p 34
###xml 50 57 50 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008792-t002">Table 2</xref>
###xml 328 335 328 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008792-t002">Table 2</xref>
The baseline mean endocannabinoid and NAE levels (Table 2) were not significantly different among the subjects in the two BMI groups except for high LEA (p = 0.04) and low DHEA (p = 0.002) plasma levels. There was a trend to elevated anandamide (AEA) levels (p = 0.06) in severely obese subjects that was not quite significant (Table 2).
###end p 34
###begin title 35
Mean plasma ECS analogue levels (picomoles/ml) by body mass index (BMI).
###end title 35
###begin p 36
###xml 0 25 0 25 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CI&#8202;=&#8202;confidence interval.</bold>
CI = confidence interval.
###end p 36
###begin p 37
###xml 0 46 0 46 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*geometric mean based on log-transformed data.</bold>
*geometric mean based on log-transformed data.
###end p 37
###begin p 38
###xml 0 19 0 19 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">**Student's t-test.</bold>
**Student's t-test.
###end p 38
###begin title 39
SNP Genotyping
###end title 39
###begin p 40
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MGLL</italic>
###xml 122 126 122 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MGLL</italic>
###xml 233 237 233 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 279 283 277 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Sipe1">[28]</xref>
###xml 506 510 504 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Sipe1">[28]</xref>
Analysis of the FAAH and MGLL genes for common gene variations or SNPs was completed and there were no common variants of MGLL found in this study. The only coding variant commonly found in the subjects in this obesity study was the FAAH 385 C-->A (P129T) as previously reported [28]. In the ECS metabolite analysis group (n = 144) frequency of the mutant A/A genotype was 7.3% in the severely obese compared to 4.2% A/A in the normal weight group, a nearly 2 fold difference similar to the previous study [28] that was not statistically significant here, probably because this study was not powered to detect a significant genotype difference.
###end p 40
###begin title 41
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
Plasma ECS Analogue Levels Correlated with the FAAH P129T Mutation
###end title 41
###begin p 42
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 192 196 192 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 471 475 471 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 504 509 504 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH-</italic>
###xml 522 529 522 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008792-t003">Table 3</xref>
###xml 570 578 570 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH 385</italic>
###xml 611 616 611 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH-</italic>
###xml 707 711 707 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 773 777 773 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 860 867 860 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008792-t004">Table 4</xref>
###xml 899 906 899 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008792-t004">Table 4</xref>
###xml 1155 1163 1155 1163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008792-g001">Figure 1</xref>
###xml 1209 1214 1209 1214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH-</italic>
###xml 1232 1237 1232 1237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH-</italic>
###xml 1247 1251 1247 1251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 1276 1280 1274 1278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 1395 1399 1391 1395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 1432 1439 1428 1435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH-WT</italic>
###xml 1638 1642 1634 1638 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 1671 1675 1667 1671 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 1759 1763 1755 1759 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 1888 1898 1884 1894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008792.s001">Dataset S1</xref>
###xml 1972 1976 1968 1972 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 2045 2053 2041 2049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008792-t003">Tables 3</xref>
###xml 2058 2059 2054 2055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008792-t004">4</xref>
To evaluate the effects of the FAAH C385A mutation on the circulating plasma levels of endocannabinoids and NAE analogues, geometric mean congener levels were compared between carriers of the FAAH 385 mutant A allele and homozygotes for the wild type (WT) C alleles Using the t-test comparing geometric mean plasma metabolite levels in the two groups, there was a significant elevation of mean anandamide (AEA) levels (p = 0.04) and related NAE levels in carriers of the FAAH 385 mutant A alleles versus FAAH-WT carriers (Table 3.). An analysis comparing severely obese FAAH 385 A carriers versus normal weight FAAH-WT subject groups using 2-way ANOVA which controls for BMI to analyze the direct effect of FAAH 385 A mutant alleles compared to subjects with the wild-type FAAH C/C genotype also showed significant (p<0.05)) elevation of AEA and related NAEs (Table 4). In the 2-way ANOVA analysis (Table 4), the interaction terms (genotype X BMI category) were not statistically significant for any of the EC analogues listed. The findings were internally consistent and statistically significant using multiple statistical methods as noted. As shown in Figure 1, comparing the four subject groups including FAAH-WT normal weight, FAAH-WT Obese, FAAH C-->A normal weight and FAAH C-->A Obese, revealed a trend toward increasing mean AEA levels with significantly elevated AEA (p<0.05) in obese FAAH mutant A allele carriers versus FAAH-WT normal weight subjects using 1-Way ANOVA with Dunnett's correction for multiple comparisons. This amounts to a modest but significant 1.14 fold higher mean AEA plasma level in severely obese mutant FAAH carriers compared to normal FAAH controls. Several other N-acylethanolamines related to AEA that are metabolized by FAAH, including PEA, OEA and LEA, were also significantly elevated in severely obese mutant carriers versus normal controls (see Dataset S1). Plasma levels of the endocannabinoid 2-AG, which is not metabolized by FAAH, showed no difference comparing severely obese and normal subjects (Tables 3 and 4).
###end p 42
###begin title 43
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
Geometric mean Anandamide (AEA) levels by BMI group and FAAH genotype.
###end title 43
###begin p 44
###xml 88 92 88 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
Error bars indicate 95% confidence intervals for geometric means. *p<0.05 compared with FAAH wildtype normal weight controls using 1-way ANOVA with Dunnett's correction for multiple comparisons but p>0.05 for all other pairwise comparisons.
###end p 44
###begin title 45
###xml 26 36 26 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH C385A</italic>
T-test Comparison between FAAH C385A carriers and wild-type subjects with BMI groups combined.
###end title 45
###begin title 46
Comparison of Mean Plasma ECS Analogue Levels by FAAH 385 Genotype Controlling for BMI.
###end title 46
###begin title 47
Discussion
###end title 47
###begin p 48
###xml 69 73 69 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 188 195 188 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008792-t003">Table 3</xref>
###xml 197 205 197 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008792-g001">Figure 1</xref>
###xml 350 354 350 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 427 431 427 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 441 448 441 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008792-t004">Table 4</xref>
###xml 450 458 450 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008792-g001">Figure 1</xref>
###xml 464 472 464 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008792-g001">Figure 1</xref>
###xml 578 583 578 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH-</italic>
###xml 618 628 618 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH 385 A</italic>
###xml 849 853 849 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 911 915 911 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 949 953 949 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 1087 1091 1085 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 1207 1215 1203 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008792-g001">Figure 1</xref>
###xml 1605 1613 1601 1609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008792-t004">Tables 4</xref>
###xml 1618 1626 1614 1622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008792-g001">Figure 1</xref>
###xml 1727 1731 1723 1727 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
The principal new findings of this study were that subjects with the FAAH 385 A mutant alleles controlling for BMI had modest but significant elevation (p = 0.04) of AEA and related NAEs (Table 3; Figure 1) There was also modest but significantly elevated (p<0.05) circulating mean plasma levels of anandamide (AEA) in severely obese carriers of the FAAH 385 mutant A alleles compared to normal BMI subjects with the wild-type FAAH genotype Table 4; Figure 1). In Figure 1, there is the appearance of elevated AEA levels in several groups but only the comparison of the control FAAH-WT normal weight subjects with the FAAH 385 A carrier obese was statistically significant (p<0.05). Because plasma levels of N-acylethanolamine analogues related to AEA, including PEA, OEA and LEA, are significantly elevated in severely obese carriers of the mutant FAAH 385 A alleles, this supports the concept of a functional FAAH enzyme mutation in subjects with FAAH 385 C-->A SNPs. Taken together, these findings provide further evidence of activation of the ECS in severely obese subjects with the FAAH 385 C-->A mutation. Despite the relatively small subject cohort, tight plasma ranges and statistical significance (Figure 1) was achieved by using highly sensitive triple quadrupole mass spectroscopy methods. All statistical methods using both the original dataset and log-transformed dataset confirmed the internal and external validity of this study. These findings are statistically robust with significant two-sided p values ranging from p = 0.04 to p<0.05 in the case of AEA to p = 0.003 in the case of OEA (Tables 4 and Figure 1). Although there is a modest 1.14 fold elevation of mean plasma AEA levels in severely obese mutant FAAH carriers, the findings are nevertheless statistically significant in this careful case-controlled study.
###end p 48
###begin p 49
###xml 296 300 296 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Engeli1">[13]</xref>
###xml 302 306 302 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Gaetani1">[15]</xref>
###xml 308 312 308 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Engeli2">[17]</xref>
###xml 314 318 314 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Engeli3">[26]</xref>
###xml 353 357 353 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Engeli2">[17]</xref>
###xml 139 145 <span type="species:ncbi:9606">humans</span>
These findings are noteworthy because endocannabinoid signaling molecules like AEA are known to regulate food intake and fat metabolism in humans. The role of endocannabinoid system dysregulation as a risk factor in the development of obesity has been the subject of considerable recent interest [13], [15], [17], [26]. Activation of the ECS in obesity [17] has the potential to identify clinically useful biomarkers of ECS risk factors that may contribute to severe obesity through appetite stimulation, high fat intake and fat metabolism.
###end p 49
###begin p 50
###xml 74 78 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 169 173 169 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 325 329 325 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 350 354 350 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 682 686 680 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 887 894 885 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008792-t004">Table 4</xref>
###xml 997 1001 995 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 1024 1032 1022 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008792-g001">Figure 1</xref>
###xml 1257 1261 1255 1259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-OseiHyiaman1">[12]</xref>
###xml 1263 1267 1261 1265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Bellocchio1">[16]</xref>
In the present study, we present the first evidence of a direct effect of FAAH 385 A mutant alleles on elevated mean basal levels of anandamide (AEA) in carriers of the FAAH P129T mutation. This is substantiated by demonstration of several of elevated N-acylethanolamine analogues related to AEA that are also metabolized by FAAH. In this study, the FAAH 385 C-->A (P129T) mutant genotype, which is the principal catabolic enzyme of many N-acyl ethanolamine ECS signaling molecules, has the same approximately 2-fold prevalence (7.3% vs. 4%) in severely obese subjects compared to normal BMI subjects observed in a previous study (28). Among both obese and normals, carriers of the FAAH 385 minor A alleles had higher levels of AEA and other NAEs, except 2-AG which is not metabolized by FAAH. Likewise, all endocannabinoid levels were positively correlated with each other except 2-AG (Table 4). Of particular interest is the significant (p<0.05) but modest elevation of AEA in subjects with the FAAH 385 mutant A alleles (Figure 1), since AEA activates the CB1 receptor and has the potential to stimulate appetite and feeding behavior as well as modulate several metabolic functions including fatty acid metabolism and contributes to diet-induced obesity [12], [16].
###end p 50
###begin p 51
###xml 107 111 107 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 214 218 214 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 270 274 270 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Sipe1">[28]</xref>
###xml 372 376 372 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Jensen1">[32]</xref>
###xml 468 472 468 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 516 520 516 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Monteleone2">[33]</xref>
###xml 638 642 638 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 699 703 699 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Papazoglou1">[34]</xref>
###xml 831 835 831 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 914 918 914 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 983 987 983 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Sipe1">[28]</xref>
###xml 989 993 989 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008792-Monteleone2">[33]</xref>
###xml 1026 1030 1026 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 1043 1047 1043 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MGLL</italic>
###xml 1284 1288 1284 1288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 36 41 <span type="species:ncbi:9606">human</span>
At the present time, there are four human clinical studies investigating the association of the functional FAAH P129T mutation with obesity. In two larger studies, one demonstrated a significant association of the FAAH P129T genotype variant with overweight and obesity [28] and one study showed no significant association of this variant with fat accumulation phenotypes [32]. In two smaller clinical studies, one confirmed the significant over-representation of the FAAH 385 A alleles in overweight/obese subjects [33] and one study comparing healthy and obese subjects with metabolic syndrome found no significant association with the FAAH P129T variant after correction for multiple comparisons [34]. Thus, more clinical studies with comparable subject cohorts are needed to evaluate the significance of the association of the FAAH 385 A mutant alleles with overweight and obesity. Since the relatively common FAAH P129T mutation has been associated with obesity in some studies [28], [33], it is possible that other rare FAAH variants or MGLL variants may also contribute to ECS tonic activation in severely obese individuals. These significant AEA elevations suggest that mean basal plasma ECS metabolite levels measured with sensitive techniques and stratified by metabolizing FAAH enzyme genotype may be a reliable indicator of biologic dysregulation in the endocannabinoid system.
###end p 51
###begin p 52
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 254 258 254 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 457 461 457 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
###xml 590 594 590 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FAAH</italic>
This study is the first to document that the FAAH 385 A mutant alleles directly affect elevated plasma levels of AEA and related NAEs and suggests that using biomarkers including AEA, PEA, OEA and LEA plasma levels combined with genotyping for the minor FAAH 385 variant A allele may identify a new ECS-related obesity phenotype with a higher risk for severe obesity. Larger clinical obesity studies of plasma endocannabinoid and NAE levels correlated with FAAH P129T genotype are needed in normal, mildly overweight and severely obese subjects to confirm the presence of linked plasma and FAAH gene ECS biomarkers for the risk of severe obesity since independent confirmation could, in turn, lead to more selective endocannabinoid or EC analogue treatment strategies.
###end p 52
###begin title 53
Supporting Information
###end title 53
###begin p 54
(0.07 MB XLS)
###end p 54
###begin p 55
Click here for additional data file.
###end p 55
###begin p 56
Helpful TQMS technical support was provided by Dr. Sherry Niessen at Scripps Research Institute Center for Physiological Proteomics (). The authors thank Terri Gelbart, Scientific Associate, for assistance with plasma extractions.
###end p 56
###begin title 57
References
###end title 57
###begin article-title 58
Recent advances in cannabinoid research.
###end article-title 58
###begin article-title 59
Formation and inactivation of endogenous cannabinoid anandamide in central neurons.
###end article-title 59
###begin article-title 60
Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes.
###end article-title 60
###begin article-title 61
Discovery and characterization of endogenous cannabinoids.
###end article-title 61
###begin article-title 62
Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action.
###end article-title 62
###begin article-title 63
'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance.
###end article-title 63
###begin article-title 64
The endocannabinoid system: physiology and pharmacology.
###end article-title 64
###begin article-title 65
Biochemistry of the endogenous ligands of cannabinoid receptors.
###end article-title 65
###begin article-title 66
Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids.
###end article-title 66
###begin article-title 67
Endocannabinoids and related fatty acid derivatives in pain modulation.
###end article-title 67
###begin article-title 68
Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system.
###end article-title 68
###begin article-title 69
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.
###end article-title 69
###begin article-title 70
The endocannabinoid system: body weight and metabolic regulation.
###end article-title 70
###begin article-title 71
Endocannabinoid system in food intake and metabolic regulation.
###end article-title 71
###begin article-title 72
Role of endocannabinoids and their analogues in obesity and eating disorders.
###end article-title 72
###begin article-title 73
The endocannabinoid system and energy metabolism.
###end article-title 73
###begin article-title 74
Dysregulation of the endocannabinoid system in obesity.
###end article-title 74
###begin article-title 75
Endocannabinoids in the regulation of appetite and body weight.
###end article-title 75
###begin article-title 76
Endocannabinoids and the control of energy homeostasis.
###end article-title 76
###begin article-title 77
###xml 55 60 <span type="species:ncbi:9606">human</span>
Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes.
###end article-title 77
###begin article-title 78
###xml 60 65 <span type="species:ncbi:9606">human</span>
Identification of endocannabinoids and related compounds in human fat cells.
###end article-title 78
###begin article-title 79
Regulation of food intake by oleoylethanolamide.
###end article-title 79
###begin article-title 80
Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia.
###end article-title 80
###begin article-title 81
The endocannabinoid system in obesity and type 2 diabetes.
###end article-title 81
###begin article-title 82
Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa.
###end article-title 82
###begin article-title 83
###xml 55 60 <span type="species:ncbi:9606">human</span>
Activation of the peripheral endocannabinoid system in human obesity.
###end article-title 83
###begin article-title 84
###xml 106 109 <span type="species:ncbi:9606">men</span>
Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men.
###end article-title 84
###begin article-title 85
Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH).
###end article-title 85
###begin article-title 86
###xml 64 69 <span type="species:ncbi:9606">human</span>
Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use.
###end article-title 86
###begin article-title 87
###xml 36 41 <span type="species:ncbi:9606">human</span>
Endogenous ethanolamide analysis in human plasma using HPLC tandem MS with electrospray ionization.
###end article-title 87
###begin article-title 88
###xml 38 46 <span type="species:ncbi:9606">patients</span>
Anandamide and neutrophil function in patients with fibromyalgia.
###end article-title 88
###begin article-title 89
The functional Pro129Thr variant of the FAAH gene is not associated with various fat accumulation phenotypes in a population-based cohort of 5,801 whites.
###end article-title 89
###begin article-title 90
###xml 208 213 <span type="species:ncbi:9606">women</span>
The cDNA 385C to A missense polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) is associated with overweight/obesity but not with binge eating disorder in overweight/obese women.
###end article-title 90
###begin article-title 91
The fatty acid amide hydrolase (FAAH) Pro129Thr polymorphism is not associated with severe obesity in Greek subjects.
###end article-title 91
###begin p 92
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 92
###begin p 93
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This project was supported by National Institutes of Health grant #DA023448 and in part by Center for AIDS Research core grant 3 P30 AI036214-13S1, as well as a research grant and supply of subject samples from Sanofi-Aventis to JCS and BFC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 93

